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OBJECTIVES: Ankylosing spondylitis (prevalence 1% of popu-
lation) is a chronic inﬂammatory progressive disease character-
ised by pain, joint stiffness, and gradual loss of mobility leading
to severe functional impairment. There are no cost-of-illness data
available in Czech Republic or in Eastern Europe. To assess direct
and indirect costs of ankylosing spondylitis we have analysed the
data from a large patient cohort study. METHODS: Data of
1008 patients (average age 50.2 years) with ankylosing spondyli-
tis were analysed. Patients were enrolled in a patientxs organi-
sation survey named BÉÏA. Data on health care consumption and
productivity loss were collected. For calculation of indirect cost
the friction cost approach was applied. RESULTS: The average
time from diagnosis was 23 years; 61% were male. Two thirds of
patients were disabled and unable to work. The mean annual
direct cost per patient is estimated at 1259 EUR (49%) and the
indirect cost due to lost work capacity is 1314 EUR (51%). The
major contributors to the total direct costs were physiotherapy,
spa and rehabilitation clinics (67% of direct costs). Drug treat-
ment contributed to 22% and hospital admissions to 5% of
direct costs. CONCLUSION: The annual total direct plus indi-
rect costs of one patient with ankylosing spondylitis in Czech
Republic were 2573 EUR. The share of direct and indirect costs
was almost equal. Our ﬁndings provide information on the
burden of disease and a baseline for cost-effectiveness evaluation
of new costly treatments.
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OBJECTIVES: To systematically review the current literature
relating to the cost-of-illness (COI) of rheumatoid arthritis (RA).
METHODS: Medline, Embase, BIOSIS, Derwent Drug File, the
Cochrane library and NHS-EED were searched on 12th March
2007. Original studies (2002-present) reporting COI data were
included after a two-stage review process. Bibliographies of
included studies were also searched for additional citations. Data
were extracted into predeﬁned extraction grids and were analy-
sed using Microsoft Excel. RESULTS: Nine hundred and nine
unique citations were retrieved. Of these, 9 studies presented
COI results. These studies were conducted in 5 different coun-
tries (Australia, France, Germany, Sweden, and the US) from
2003–2007. Six studies adopted a societal perspective by includ-
ing direct medical and non-medical costs and indirect costs.
Patient populations across the studies ranged from only early RA
(<12 months from disease onset) to all RA patients. The use of
biological agents (including inﬂiximab, etanercept, and anakinra)
was assessed in only 3 of these studies. Annual direct costs
ranged between €3000 and €4000 in all European countries.
Lower annual direct costs were reported in the Australian analy-
sis as a result of the inclusion of all Australian adults with RA,
while substantially higher costs were found in a US study. This
could be attributed to the higher costs of medications that
included anti-TNF therapies. In terms of components of direct
costs, medications and hospitalisations were generally the cat-
egories associated with the highest costs. Indirect costs exceeded
direct costs in 5 of the 6 analyses. These ranged between 2 and 4
times the direct costs. Finally, a statistically signiﬁcant positive
correlation was found in most studies between total RA costs and
disease severity. CONCLUSION: This review of recently pub-
lished COI analyses found that RA is associated with signiﬁcant
direct and indirect costs, with the economic burden being highly
dependent on the level of functional disability.
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OBJECTIVES: To examine the resource utilization and direct
costs of care associated with comorbid cardiovascular disease
(CVD) and depression among prevalent rheumatoid arthritis
(RA) patients using retrospective health care claims data.
METHODS: Patients  18 years of age with a diagnosis of RA
January 1, 2002-December 31, 2004 were selected. The date of
the ﬁrst observed claim with an RA diagnosis following a one
year period of health plan enrollment was the “index date.”
Patients had 12-month pre-index and follow-up periods. Patients
were also required to have a diagnosis of RA and RA-related
treatment during pre-index. Based upon pre-index utilization,
patients were classiﬁed into mutually exclusive diagnosis groups:
RA with comorbid depression; RA with comorbid CVD; RA
with comorbid CVD and depression; RA alone. Annual utiliza-
tion and costs were calculated; generalized linear models (GLM)
were undertaken, controlling for demographic and clinical char-
acteristics. Analyses focused on differences in costs among
RA only vs. comorbid diagnosis groups. RESULTS: A total of
8916 patients had RA alone (86.6%), 608 had RA + CVD
(5.9%), 716 had RA + depression (7.0%), and 58 had
RA + CVD + depression (0.5%). Mean age varied by cohort
group with RA + CVD tending to be older (RA + CVD: 59 years;
RA + depression: 50 years; RA + CVD + depression: 53 years;
RA alone: 51 years). A signiﬁcantly lower proportion of patients
with RA alone had a RA-related hospitalization stay during
follow-up (5.4%) compared with other groups (RA + CVD:
9.4%; RA + depression: 0.001). In GLM modeling, adjusted
mean < 9.2%; RA + CVD + depression: 15.5%, all p annual
costs were highest for RA + CVD ($14,328) followed by
RA + CVD + depression ($13,276), RA + depression ($12,270),
and RA alone ($11,522). CONCLUSION: A signiﬁcant portion
of prevalent RA patients has comorbid CVD and/or depression
(13.4%). Comorbid depression and cardiovascular events are
associated with signiﬁcant increase in not only the annual total
medical costs, but there may also be associated increases in
RA-related utilization.
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OBJECTIVES: To compare the effectiveness of oral leﬂunomide
(Arava®) and subcutaneous metotrexate (Metoject®) using the
Number Needed to Treat (NNTs), a measure supported by the
Evidence Based Medicine approach. The effectiveness results
have been combined with Spanish annual costs to assess the
economic impact of these treatments. METHODS: An event has
been deﬁned as non-responder patient according to ACR20 and
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